Overview

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status:
Terminated

Trial end date:
2018-10-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer. Determine through pharmacokinetic evaluation(sometimes described as what the body does to a drug, refers to the movement of drug into, through and out of the body-the time and course of its absorption, bioavailability, distribution, metabolism, and excretion) whether or not the disposition of paclitaxel is affected by the concurrent administration of CRLX101.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cerulean Pharma Inc.
NewLink Genetics Corporation

Treatments:

Albumin-Bound Paclitaxel
Camptothecin
Paclitaxel